PYC commences new study on drug for eye condition Retinitis Pigmentosa type 11
PYC Therapeutics Ltd has begun a new trial into the safety and efficacy of its VP-001 drug which has been fast tracked by the FDA.
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO
Charles Armstrong
CEO
SPONSORED BY The Market Online